(5-phenyl-indol-2-yl)-methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (5-phenyl-indol-2-yl)-methanol
• 英文别名: (5-phenyl-1H-indol-2-yl)methanol
• 化学式: C₁₅H₁₃NO
• 分子量: 223.274
• InChiKey: AYESPHXUZNFRTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  36
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (5-phenyl-indol-2-yl)-methanol 在 2-碘酰基苯甲酸 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 生成 5-phenyl-1H-indole-2-carbaldehyde
  参考文献：
  名称：

  Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase

  摘要：

  In order to explore the interactions of bisphosphonate ligands with the active site and an allosteric pocket of the human farnesyl pyrophosphate synthase (hFPPS), substituted indole and azabenzimidazole bisphosphonates were designed as chameleon ligands. NMR and crystallographic studies revealed that these compounds can occupy both subpockets of the active site cavity, as well as the allosteric pocket of hFPPS in the presence of the enzyme's Mg2+ ion cofactor. These results are consistent with the previously proposed hypothesis that the allosteric pocket of hFPPS, located near the active site, plays a feedback regulatory role for this enzyme. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.089
• 作为产物：
  描述：

  ethyl 2-[2-(4-bromophenyl)hydrazinylidene]propanoate 在 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 42.0h， 生成 (5-phenyl-indol-2-yl)-methanol
  参考文献：
  名称：

  Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase

  摘要：

  In order to explore the interactions of bisphosphonate ligands with the active site and an allosteric pocket of the human farnesyl pyrophosphate synthase (hFPPS), substituted indole and azabenzimidazole bisphosphonates were designed as chameleon ligands. NMR and crystallographic studies revealed that these compounds can occupy both subpockets of the active site cavity, as well as the allosteric pocket of hFPPS in the presence of the enzyme's Mg2+ ion cofactor. These results are consistent with the previously proposed hypothesis that the allosteric pocket of hFPPS, located near the active site, plays a feedback regulatory role for this enzyme. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.089

文献信息

• Carboxylic acid derivatives as IP antagonists
  申请人：——

  公开号：US20010056100A1

  公开（公告）日：2001-12-27

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: 1 wherein: R 1 , R 2 , and R 3 are each independently in each occurrence aryl or heteroaryl; R 4 is —COOH or tetrazolyl; A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.

  这项发明涉及一类通常为IP受体拮抗剂的化合物，其由以下式I表示： 其中： R1、R2和R3在每次出现时各自独立地为芳基或杂环芳基； R4为—COOH或四唑基； A、B、m、n和r如规范中定义； 或其各个异构体、外消旋或非外消旋异构体混合物，或其药用可接受盐或溶剂合物。该发明还涉及含有这种化合物的药物组合物，以及将其用作治疗剂的方法和其制备方法。
• [EN] CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE UTILISES COMME DES ANTAGONISTES D'IP
  申请人：HOFFMANN LA ROCHE

  公开号：WO2001068591A1

  公开（公告）日：2001-09-20

  This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula (I) wherein R?1, R2, and R3¿ are each independently in each occurrence aryl or heteroaryl, R4 is -COOH or tetrazolyl, A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, processes for their preparation and their use as therapeutic agents.

  本发明涉及一类化合物，通常为IP受体拮抗剂，其由式（I）表示，其中R1、R2和R3在每次出现时均独立地为芳基或杂环芳基，R4为-COOH或四唑基，A、B、m、n和r如规范中所定义；或其各个异构体，混合物，或其药学上可接受的盐或溶剂。本发明还涉及含有这种化合物的药物组合物，其制备方法以及作为治疗剂的用途。
• CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1265853A1

  公开（公告）日：2002-12-18
• US6693098B2
  申请人：——

  公开号：US6693098B2

  公开（公告）日：2004-02-17
• US7056903B2
  申请人：——

  公开号：US7056903B2

  公开（公告）日：2006-06-06